Professor
City of Hope, Irvine, CA, USA
I am professor of hematology/hematopoietic cell transplant and the director of the Judy and Bernard Briskin Center for Myeloma at the City of Hope Cancer Center. In that capacity I have run multiple first in human phase I trials, including most recently three trials with bispecific antibodies which I presented at ASCO 2021 and EHA 2021. In regards to commitment to national organizations. I am past chair of the myeloma committee of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), the national cooperative group of the leading transplant centers. I was the PI of two of the largest myeloma transplant trials conducted through the BMT CTN and am the current co chair of the SWOG S1803 MM transplant study investigating the role of MRD directed therapy in maintenance post HCT . My research in myeloma extends to a nationwide presence, including serving as past chair of the plasma cell/ lymphoma committee of the American Society of Clinical Oncology (ASCO), previous co chair of theCIBMTR plasma cell committee, and past chair of the education committee for ASTCT. I have served as a member for the ASH communications committee, an abstract reviewer for the myeloma section and chaired the myeloma abstract review section. My research interests are in mechanisms of resistance to myeloma antibody directed therapies.